Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Cleveland Clinical Foundation

12 Feb, 2019 ,

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Source

OPHTHALMOLOGY

Also Read

His Bundle Pacing in Bradycardia and Heart Failure

Apr 22, 2019

Orchidopexy Randomized Clinical Assessment

Apr 22, 2019

Quality of Life in Patients With Primary Sclerosing Cholangitis

Apr 22, 2019

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Apr 22, 2019